Scinai Immunotherapeutics (FRA:2F5) Dividends per Share : €0.00 (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scinai Immunotherapeutics Dividends per Share?

Scinai Immunotherapeutics's dividends per share for the three months ended in Sep. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Scinai Immunotherapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Scinai Immunotherapeutics Dividends per Share Historical Data

The historical data trend for Scinai Immunotherapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Dividends per Share Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Scinai Immunotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Scinai Immunotherapeutics's Dividends per Share

For the Biotechnology subindustry, Scinai Immunotherapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinai Immunotherapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Scinai Immunotherapeutics Dividends per Share Calculation

Dividends paid to per common share.

Scinai Immunotherapeutics (FRA:2F5) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Scinai Immunotherapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	7.568
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Scinai Immunotherapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (FRA:2F5) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

SCNI:USA

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Headlines

No Headlines